86 related articles for article (PubMed ID: 8513471)
21. [Systemic therapy of low malignancy non-Hodgkin lymphomas].
Wörmann B; Buske C; Hiddemann W
Praxis (Bern 1994); 1998 Jun; 87(23):806-11. PubMed ID: 9654987
[TBL] [Abstract][Full Text] [Related]
22. [Non-Hodgkin's lymphoma: treatment and outcome of children with advanced disease].
Tsurusawa M
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1050-5. PubMed ID: 10431576
[TBL] [Abstract][Full Text] [Related]
23. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
24. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
Dorfman DM; Shahsafaei A
Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
[TBL] [Abstract][Full Text] [Related]
25. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
27. [Dose-effects and chemotherapy dose intensity of aggressive non-Hodgkin's lymphomas in the adult].
Solal-Céligny P; Colombat P
Bull Cancer; 1998 Mar; 85(3):232-8. PubMed ID: 9752311
[TBL] [Abstract][Full Text] [Related]
28. [Lymphomas: new therapeutic options].
Weide R; Heymanns J; Thomalla J; Köppler H
MMW Fortschr Med; 2005 Jun; 147(24):28, 30-1. PubMed ID: 16001530
[TBL] [Abstract][Full Text] [Related]
29. [Hematologic tumors].
Ogawa M
Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():165-72. PubMed ID: 10410671
[TBL] [Abstract][Full Text] [Related]
30. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
31. [Radiotherapy of primary non-Hodgkin lymphoma of the stomach].
Hartmann A; Roth SL
Praxis (Bern 1994); 1996 Jun; 85(23):765-70. PubMed ID: 8693245
[TBL] [Abstract][Full Text] [Related]
32. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
Jezersek Novaković B; Vovk M; Juznic Setina T
Ann Hematol; 2006 Dec; 85(12):849-56. PubMed ID: 16944146
[TBL] [Abstract][Full Text] [Related]
33. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.
Cosset JM; Fermé C; Noordijk EM; Dubray BM; Thirion P; Henry-Amar M
Semin Radiat Oncol; 1996 Jul; 6(3):185-195. PubMed ID: 10717177
[TBL] [Abstract][Full Text] [Related]
34. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
[TBL] [Abstract][Full Text] [Related]
35. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
36. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
Mayer J; Navrátil M; Vásová J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity].
Nie DH; Hu WH; Gao YH; Wu Y; Zhang SP
Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):312-4. PubMed ID: 15312373
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic possibilities in non-Hodgkin's lymphoma].
Klener P
Vnitr Lek; 1997 May; 43(5):320-5. PubMed ID: 9601857
[TBL] [Abstract][Full Text] [Related]
39. [Interferon alfa in the treatment of malignant lymphomas].
Adam Z
Vnitr Lek; 1994 Apr; 40(4):255-8. PubMed ID: 8184589
[TBL] [Abstract][Full Text] [Related]
40. [Malignant lymphomas. Non-Hodgkin's lymphomas (NHL). II. Therapeutic planning].
Neretto G
Minerva Med; 1980 Apr; 71(13):996-8. PubMed ID: 7375012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
